Cyclophosphamide
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Cyclophosphamide
- Pharmacist Assessment Report
- Cyclophosphamide: Vertebral anomalies and variable endocrine and T-cell dysfunction
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cyclophosphamide: Vertebral anomalies and variable endocrine and T-cell dysfunction
One-Sentence Summary
Cyclophosphamide is a DNA-alkylating cytotoxic agent that has long been marketed in India. The TxGNN model predicts it may be relevant to vertebral anomalies and variable endocrine and T-cell dysfunction, with a score of 0.9938. No clinical trials and no publications support this prediction, so it rests on computation alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Vertebral anomalies and variable endocrine and T-cell dysfunction |
| TxGNN Prediction Score | 0.9938 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Cyclophosphamide is a prodrug that is activated in the liver. Its active metabolites alkylate DNA, which kills rapidly dividing cells and also suppresses immune cells.
The predicted condition is a rare disorder that involves T-cell dysfunction. This is a problem for the prediction. An immunosuppressive, cytotoxic alkylating agent could plausibly worsen immune function rather than improve it. No mechanistic rationale found so far supports benefit, and the high score should be treated as a computational signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
All 20 licences in the local records are valid single-ingredient products, and the list may be partial. The local records carry no approved-indication text. Main products:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 39643 | Cycloxan 200mg Injection | vial of 1 Injection | Not recorded |
| 47544 | Cyphos 1000mg Injection | vial of 1 Injection | Not recorded |
| 49209 | Cycram 1000mg Injection | vial of 1 Injection | Not recorded |
| 72341 | Endoxan Tablet | strip of 10 tablets | Not recorded |
| 175621 | Phosmid 50mg Tablet | strip of 10 tablets | Not recorded |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent, nitrogen mustard class) |
| Myelosuppression Risk | High (leukopenia and neutropenia are dose-limiting) |
| Emetogenicity Classification | Moderate at usual doses; high at high intravenous doses |
| Monitoring Items | CBC with differential, liver and renal function, electrolytes, urinalysis (bladder toxicity) |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Please also refer to the package insert warnings and precautions.
Safety Considerations
- Drug Interactions: 481 interactions are recorded. Examples include:
- Moderate: amphotericin B (including lipid, cholesteryl sulfate and liposomal forms), bupropion, aprepitant, metronidazole, nitisinone, troglitazone.
- Moderate (antidiabetic agents): sulfonylureas (chlorpropamide, acetohexamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide), nateglinide and repaglinide.
- Minor: levofloxacin, ondansetron.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or publications (evidence level L5). The disorder involves T-cell dysfunction, and an immunosuppressive cytotoxic agent could worsen it. High-risk toxicity (myelosuppression) adds to the concern.
To proceed, the following is needed:
- Mechanism of action data and a mechanistic case for benefit in this disorder
- Preclinical or case-level evidence directly studying this disease
- Package insert warnings and contraindications from the local records
- A risk assessment for immune suppression in patients with T-cell dysfunction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.